Pfizer, Edelman team up on a new grant initiative

NEW YORK: The Pfizer Foundation has launched a new grant initiative with a global communications push, supported by Edelman. According to a Pfizer communications officer, Edelman is lending assistance to the foundation's in-house team.

NEW YORK: The Pfizer Foundation has launched a new grant initiative with a global communications push, supported by Edelman. According to a Pfizer communications officer, Edelman is lending assistance to the foundation's in-house team.

Imraan Munshi, communications director for Pfizer, said that much of the work for the project is being handled in-house, with Edelman assisting on coordination efforts with the 15 NGOs, scattered across 26 countries, involved in the program.

The first round of the Global Health Partnership grants have already been awarded. Grants totaling $33 million are slated to address the dual challenges of cancer and tobacco control. Munshi said communications efforts have focused on print and broadcast media outreach about the program, managing expectations, and showing how the program has metrics in place. Johns Hopkins University Bloomberg School of Public Health will evaluate the program's success.

Another round of efforts are expected on the local level, with announcements and media relations to take place in each individual location with local Pfizer representatives, Munshi said.

"Usually when you're involved with projects like this, you want to go on record and publicize it all once you have the results to show for it," he explained. "This one's a little different in that we had to announce the program, and now subsequent market announcements will follow."

Partners to receive grants include the American Cancer Society, a Foundation ally for the last five years in Latin American and China; the Korean National Council of Women; the China Tobacco Control Association; and Philippine Business for Social Progress.

The Pfizer Foundation operates independently from the corporation, and though the drug company produces oncology and smoking cessation drugs, the program is not tied to any corporate reputation programs on behalf of the pharmaceutical maker, Munshi noted.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.